Antengene Corporation, a biopharmaceutical company dedicated to developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, and WuXi Biologics have signed a strategic cooperation Memorandum of Understanding (MoU) to collaborate on the development and production of novel drugs, and jointly promote the R&D of innovative oncology therapies.
 
China’s cancer incidence and mortality have been increasing in recent years. Low rates of survival and access to innovative therapies are persistent obstacles to local cancer treatment. With the vision of “Treating patients beyond borders,” Antengene is committed to bringing novel mechanisms of action and anti-tumor therapies to patients in China, the rest of Asia Pacific and around the world.
 
As a leading global open-access biologics technology platform, Wuxi Biologics offers end-to-end solutions based on its sophisticated R&D system and technological platform to advance the process of promoting drug R&D from concept to commercial manufacturing. Through the collaboration, Antengene and WuXi Biologics will make full use of their extensive resources and professional capabilities to accelerate the research and development of innovative cancer therapies and provide patients with high-quality and affordable treatment plans as soon as possible .
 
“We are very glad to launch a strategic cooperation with WuXi Biologics. This cooperation is a timely decision. WuXi Biologics has first-class biopharmaceutical capabilities and could empower us with advanced technology,” said Dr. Jay Mei, founder, chairman and CEO of Antengene, “At present, Antengene has carried out a comprehensive layout for the research and development of innovative cancer medicines, and continues to promote the science-oriented R&D of anti-tumor drugs such as small molecule drugs, monoclonal drugs and bispecific antibody drugs. We are looking forward to enhancing the quality of research and development and leveraging complementary strengths of both companies in order to ultimately benefit a wider range of cancer patients.”
 
Dr. Chris Chen, CEO of WuXi Biologics, added, “We are pleased to establish a strategic cooperation with Antengene. Through our diversified and integrated biologics technology platform, WuXi Biologics will continue to empower Antengene to accelerate the R&D process of innovative oncology therapies. We look forward to working together to achieve a win-win situation based on our capabilities and advantages and make positive contribution to the health and wellness of patients in China and the world.”